E

Evotec SE
XETRA:EVT

Watchlist Manager
Evotec SE
XETRA:EVT
Watchlist
Price: 8.5 EUR -15.59% Market Closed
Market Cap: 1.5B EUR
Have any thoughts about
Evotec SE?
Write Note

Evotec SE
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Evotec SE
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
E
Evotec SE
XETRA:EVT
Long-Term Debt
€416.5m
CAGR 3-Years
-3%
CAGR 5-Years
0%
CAGR 10-Years
58%
Gerresheimer AG
XETRA:GXI
Long-Term Debt
€654m
CAGR 3-Years
-8%
CAGR 5-Years
-1%
CAGR 10-Years
5%
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Long-Term Debt
€69.2m
CAGR 3-Years
173%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Evotec SE
Glance View

Market Cap
1.5B EUR
Industry
Life Sciences Tools & Services

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,521 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

EVT Intrinsic Value
12.69 EUR
Undervaluation 33%
Intrinsic Value
Price
E

See Also

What is Evotec SE's Long-Term Debt?
Long-Term Debt
416.5m EUR

Based on the financial report for Sep 30, 2024, Evotec SE's Long-Term Debt amounts to 416.5m EUR.

What is Evotec SE's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
58%

Over the last year, the Long-Term Debt growth was -6%. The average annual Long-Term Debt growth rates for Evotec SE have been -3% over the past three years , and 58% over the past ten years .

Back to Top